Clinical Immunology · CD70 Deficiency

Treating Complications: From Lymphoma to Transplant

At a Glance

CD70 deficiency complications need expert, individualized care: EBV-related lymphoma and HLH may require urgent chemotherapy or immune-directed treatment, while a hematopoietic stem cell transplant may provide a potentially definitive cure but carries serious risks.

While many aspects of CD70 deficiency are managed with active surveillance, some complications—specifically EBV-associated lymphomas and HLH—require urgent, intensive medical intervention. Because this condition is so rare, there is no single established protocol for treatment; instead, expert specialists select therapies tailored to the specific complication, while evaluating the potential for a curative hematopoietic stem cell transplant (HSCT).

Treating EBV-Related Lymphomas

If a biopsy confirms that the Epstein-Barr Virus (EBV) has caused cells to grow into a lymphoma (blood cancer), the treatment depends on the specific pathology, staging, and patient factors.

Hodgkin Lymphoma: This has been commonly reported in CD70 deficiency ^[1]. Depending on the case, an expert oncology team may use established chemotherapy regimens (examples include ABVD or COPP) ^[2]. In some cases, targeted drugs like brentuximab vedotin are considered to attack specific proteins on the cancer cells ^[3]^[4].
Plasmablastic Lymphoma (PBL): This is a rarer form of lymphoma documented in this condition ^[5]. Depending on the clinical scenario, intensive chemotherapy combinations like infusional EPOCH may be considered ^[6]^[7].
Targeted Immunotherapy: If the lymphoma cells are “CD20-positive,” a drug called rituximab may be added to help lower the viral load while chemotherapy works ^[8]^[9].

Managing HLH Emergencies

Hemophagocytic Lymphohistiocytosis (HLH) is a life-threatening complication where the immune system becomes dangerously over-activated ^[10]. Suspected HLH requires urgent specialist care.

When HLH occurs, the goal is to calm the hyperinflammation. This often involves high-dose steroids (like dexamethasone) and chemotherapy (like etoposide) ^[11]^[10]. In specialized centers, newer cytokine-directed therapies (such as anakinra or emapalumab) may be utilized to target the specific inflammatory signals, often as a bridge to transplant ^[12]^[13].

The Curative Option: Stem Cell Transplant (HSCT)

A hematopoietic stem cell transplant (HSCT) is currently a potentially definitive cure for the underlying hematopoietic defect in CD70 deficiency. By replacing the faulty immune system with healthy donor cells, the body can restore its ability to control EBV ^[14]^[15].

Survival Data: In a small, combined study of patients with CD70 and CD27 deficiencies, 95% of those transplanted survived ^[14]. However, these statistics come from very limited expert-center cohorts and cannot guarantee an individual outcome.
Additional Reports: In an isolated case report, a patient with CD70 deficiency and severe Type 1 Diabetes experienced significant improvement in blood sugar control after HSCT ^[16]. This is a single observation and not an expected benefit of transplant.
Significant Risks: HSCT is a high-risk procedure requiring intense “conditioning” chemotherapy. Risks include transplant-related mortality, graft failure, severe infections, organ toxicity, potential infertility, and Graft-versus-Host Disease (GVHD), where the new immune system attacks the patient’s body ^[17]^[18].

When is the “Right” Time for Transplant?

Deciding when to pursue a transplant is highly individualized. Because the disease course can be stable for years or rapidly progress, timing depends on many clinical variables ^[19].

Risk-Benefit Factors: A stable EBV viral load alone does not dictate the decision. Timing also depends on the history of HLH, lymphoma, infection burden, organ damage, and donor availability ^[15]. Younger age and fewer comorbidities generally favor better outcomes.
Timing of Transplant: For patients who develop a malignancy, HSCT is often considered once the cancer is in remission ^[14]. For those who remain clinically stable on active surveillance, the decision to proceed with a high-risk transplant requires careful weighing of immediate risks against future complications.

This decision requires a multidisciplinary team—including an immunologist, an oncologist, and a specialized transplant team—to weigh the unique history against the known risks ^[15].

Common questions in this guide

How is EBV-related lymphoma treated in someone with CD70 deficiency?

Treatment is individualized according to the lymphoma type, biopsy findings, stage, and the patient's overall health. Hodgkin lymphoma may be treated with established chemotherapy, brentuximab vedotin may be considered in some cases, and rituximab may be added when lymphoma cells are CD20-positive; plasmablastic lymphoma may require intensive chemotherapy.

What happens if HLH develops with CD70 deficiency?

Hemophagocytic lymphohistiocytosis, or HLH, is a life-threatening overactivation of the immune system that requires urgent specialist care. Treatment may include high-dose dexamethasone and etoposide, while anakinra or emapalumab may be used in specialized centers to control inflammation, sometimes as a bridge to transplant.

Can a stem cell transplant cure CD70 deficiency?

A hematopoietic stem cell transplant may provide a potentially definitive treatment by replacing the faulty immune system with healthy donor cells and restoring the body's ability to control EBV. It is not guaranteed to work for every patient and carries substantial risks, so the decision requires individualized specialist assessment.

When is a stem cell transplant considered for CD70 deficiency?

Timing depends on the patient's history of HLH, lymphoma, infections, organ damage, donor availability, age, and other health conditions. When lymphoma is present, transplant is often considered after the cancer reaches remission; people who remain stable may weigh continued surveillance against the risks of an early transplant.

What are the main risks of HSCT for CD70 deficiency?

HSCT requires intensive conditioning chemotherapy and can cause transplant-related death, graft failure, severe infections, organ toxicity, infertility, or graft-versus-host disease. The transplant team should explain which risks are most relevant to the patient's conditioning plan and health history.

Which specialists should guide treatment decisions for CD70 deficiency complications?

A multidisciplinary team should include an immunologist, an oncologist, and a transplant specialist familiar with the CD27-CD70 pathway. Working together, they can interpret the lymphoma or HLH history and balance treatment benefits against transplant risks.

Get notified when new evidence is published on EBV-induced lymphoproliferative disease due to CD70 deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (19)

1
Combined immunodeficiency and Epstein-Barr virus-induced B cell malignancy in humans with inherited CD70 deficiency.
Abolhassani H, Edwards ES, Ikinciogullari A, et al.
The Journal of experimental medicine 2017; (214(1)):91-106 doi:10.1084/jem.20160849.
PMID: 28011864
2
NF-κB1 Haploinsufficiency Causing Immunodeficiency and EBV-Driven Lymphoproliferation.
Boztug H, Hirschmugl T, Holter W, et al.
Journal of clinical immunology 2016; (36(6)):533-40 doi:10.1007/s10875-016-0306-1.
PMID: 27338827
3
A Rare Case of Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) Presenting With Hemophagocytosis Complicated With Hodgkin Lymphoma.
Cansever M, Zietara N, Chiang SCC, et al.
Journal of pediatric hematology/oncology 2020; (42(2)):156-159 doi:10.1097/MPH.0000000000001487.
PMID: 31033788
4
Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease.
LaCasce AS
Hematological oncology 2019; (37 Suppl 1()):87-91 doi:10.1002/hon.2589.
PMID: 31187532
5
Pediatric Plasmablastic Lymphoma in the Setting of CD70 Deficiency.
Baskin K, Vural O, Haskologlu S, et al.
Journal of pediatric hematology/oncology 2024; (46(8)):438-441 doi:10.1097/MPH.0000000000002948.
PMID: 39262383
6
Plasmablastic Lymphoma: 2026 Update on Diagnosis, Risk Stratification, and Management.
Castillo JJ, Beltrán BE, Florindez JA, et al.
American journal of hematology 2026; (101(8)):1997-2006 doi:10.1002/ajh.70373.
PMID: 42138287
7
Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial).
Ramos JC, Sparano JA, Chadburn A, et al.
Blood 2020; (136(11)):1284-1297 doi:10.1182/blood.2019003959.
PMID: 32430507
8
Rituximab-containing immuno-chemotherapy regimens are effective for the elimination of EBV for EBV-HLH with only and mainly B lymphocytes of EBV infection.
Meng GQ, Wang JS, Wang YN, et al.
International immunopharmacology 2021; (96()):107606 doi:10.1016/j.intimp.2021.107606.
PMID: 33826999
9
Management of Epstein-Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation.
Liu L, Liu Q, Feng S
Therapeutic advances in hematology 2020; (11()):2040620720910964 doi:10.1177/2040620720910964.
PMID: 32523657
10
Virus-triggered secondary hemophagocytic lymphohistiocytosis.
Imashuku S, Morimoto A, Ishii E
Acta paediatrica (Oslo, Norway : 1992) 2021; (110(10)):2729-2736 doi:10.1111/apa.15973.
PMID: 34096649
11
Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study.
Bergsten E, Horne A, Aricó M, et al.
Blood 2017; (130(25)):2728-2738 doi:10.1182/blood-2017-06-788349.
PMID: 28935695
12
Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.
Ghonge A, Samperio VM, Hamoud M, Dasanu CA
Expert opinion on biological therapy 2026; (26(6)):577-585 doi:10.1080/14712598.2026.2693759.
PMID: 42334930
13
Low-dose emapalumab combined with chemotherapy for adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
Zhu W, Zhou F, Song Y, et al.
Transplant immunology 2025; (88()):102162 doi:10.1016/j.trim.2024.102162.
PMID: 39719162
14
Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency.
Ghosh S, Köstel Bal S, Edwards ESJ, et al.
Blood 2020; (136(23)):2638-2655 doi:10.1182/blood.2020006738.
PMID: 32603431
15
Novel indications for hematopoietic stem cell transplantation in inborn errors of immunity.
Laberko A, Gennery AR
Expert review of clinical immunology 2026; (22(2)):183-193 doi:10.1080/1744666X.2026.2641540.
PMID: 41786511
16
Severe onset type 1 diabetes mellitus with unusual manifestations due to CD70 deficiency: novel pathway in deciphering the etiopathogenesis of type 1 diabetes mellitus, and the experience with hematopoietic stem cell transplantation.
Unsal Y, Sancak E, Çelik Ertaş NB, et al.
Pediatric diabetes 2026; (2026()):e003 doi:10.48130/pedi-0026-0004.
PMID: 42812140
17
Haploidentical hematopoietic stem cell transplantation for adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
Li Z, Wang Y, Wang J, et al.
Leukemia & lymphoma 2018; (59(1)):77-84 doi:10.1080/10428194.2017.1330467.
PMID: 28573910
18
Defining and Grading Infections in Clinical Trials Involving Hematopoietic Cell Transplantation: A Report From the BMT CTN Infectious Disease Technical Committee.
Shahid Z, Etra AM, Levine JE, et al.
Transplantation and cellular therapy 2024; (30(5)):540.e1-540.e13 doi:10.1016/j.jtct.2024.03.001.
PMID: 38458478
19
CD70 Deficiency Associated With Chronic Epstein-Barr Virus Infection, Recurrent Airway Infections and Severe Gingivitis in a 24-Year-Old Woman.
Krüger R, Martin E, Dmytrus J, et al.
Frontiers in immunology 2020; (11()):1593 doi:10.3389/fimmu.2020.01593.
PMID: 32849540

This page is for informational purposes only and does not constitute medical advice. Decisions about lymphoma, HLH, or HSCT in CD70 deficiency should be made with specialists experienced in immunodeficiency, oncology, and transplant care.